Boothbay Fund Management’s Altimmune ALT Stock Holding History

Boothbay Fund Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-68,400	Closed	-$342K	–	1429
2025 Q1	$342K	Buy	68,400 +20,600	+43%	+$130K	0.01%	1008
2024 Q4	$345K	Buy	+47,800	New	+$365K	0.01%	1027
2023 Q2	–	Sell	-256,400	Closed	-$1.08M	–	1774
2023 Q1	$1.08M	Buy	+256,400	New	+$3.05M	0.02%	956

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boothbay Fund Management's ALT Position: Q2 2023 in Review

Boothbay Fund Management sold out of Altimmune (ALT) in Q2 2023, closing a stake of 175,860 shares — an estimated $742K sold.

Boothbay Fund Management first reported a position in ALT in Q2 2020 and held it in 8 quarters. The position peaked at $1.5M in Q2 2022. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

Boothbay Fund Management reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 175,860 Altimmune shares in Q2 2023, an estimated $742K.
Boothbay Fund Management first reported a position in Altimmune in Q2 2020 and held it in 8 quarters.
Boothbay Fund Management's Altimmune position peaked at $1.5M in Q2 2022.
120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.